Context Therapeutics Inc.
CNTX
$0.784
$0.0111.42%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -0.92% | -4.52% | -10.30% | -10.50% | -6.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.35% | 47.79% | 0.69% | 22.78% | 68.49% |
| Operating Income | -19.35% | -47.79% | -0.69% | -22.78% | -68.49% |
| Income Before Tax | -11.52% | -45.30% | 0.87% | -20.43% | -61.53% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -11.52% | -45.30% | 0.87% | -20.43% | -61.53% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -11.52% | -45.30% | 0.87% | -20.43% | -61.53% |
| EBIT | -19.35% | -47.79% | -0.69% | -22.78% | -68.49% |
| EBITDA | -19.36% | -47.83% | -0.70% | -22.79% | -119.25% |
| EPS Basic | 64.79% | 29.86% | 9.43% | -20.42% | -61.51% |
| Normalized Basic EPS | 64.79% | 29.85% | 9.41% | -23.95% | -67.16% |
| EPS Diluted | 61.96% | 29.86% | 9.43% | -20.42% | -61.51% |
| Normalized Diluted EPS | 64.79% | 29.85% | 9.41% | -23.95% | -67.16% |
| Average Basic Shares Outstanding | 265.36% | 162.07% | 61.06% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 265.36% | 162.07% | 61.06% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |